TherapeuticsMD (TXMD) Stock Climbs, Oppenheimer Sees 80% Upside
Oppenheimer analyst Jay Olson today offers up some tidbits about the upcoming launch of TherapeuticsMD’s (NYSE :TXMD) lead drug Imvexxy. Olson rates TXMD an Outperform with a $12 price target, which implies an upside of over 80% from current levels.
TXMD announced last week that the FDA approved Imvexxy for treating symptoms of VVA. The drug will be launched at the 4mcg and 10mcg doses and the label will carry the estrogen class black box warning.
Olson opined, “TXMD presented a compelling launch plan including medical, marketing and reimbursement strategies for Imvexxy to treat moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), due to menopause. The innovative launch plan leverages what we consider Imvexxy’s best-in-class profile based on safety, efficacy and convenience. According to widely accepted guidelines from regulators and clinicians, patients should begin treatment at the lowest available dose, meaning that Imvexxy should now become the first-line treatment of choice for most cases of dyspareunia. We believe TXMD has the capabilities in place to bring this vision into reality.”
The analyst continued, “We forecast 4 annual scripts per patient with 1 loading dose priced at $405 and 3 maintenance doses at $180 each and 35% total discounts, leading to estimated peak sales of $400M for Imvexxy in 2030, the low end of TXMD guidance. We update our model to reflect Imvexxy launch plans and reiterate our $12 PT.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jay Olson has a yearly average return of 1.2% and a 46% success rate. Olson has a -10.1% average return when recommending TXMD, and is ranked #2501 out of 4819 analyst.
Most analysts back Olson’s confident take on the biotech firm, as TipRanks analytics showcase TXMD as a Strong Buy. Based on 9 analysts polled in the last 3 months, 8 rate a Buy on TherapeuticsMD stock while 1 maintains a Hold. The 12-month average price target stands at $14.13, marking a nearly 114% upside from where the stock is currently trading.